Literature DB >> 7683208

The importance of methylthio-IMP for methylmercaptopurine ribonucleoside (Me-MPR) cytotoxicity in Molt F4 human malignant T-lymphoblasts.

M H Vogt1, E H Stet, R A De Abreu, J P Bökkerink, L H Lambooy, F J Trijbels.   

Abstract

The importance of methyl-thioIMP (Me-tIMP) formation for methylmercaptopurine ribonucleoside (Me-MPR) cytotoxicity was studied in Molt F4 cells. Cytotoxicity of Me-MPR is caused by Me-tIMP formation with concomitant inhibition of purine de novo synthesis. Inhibition of purine de novo synthesis resulted in decreased purine nucleotide levels and enhanced 5-phosphoribosyl-1-pyrophosphate (PRPP) levels, with concurrent increased pyrimidine nucleotide levels. The Me-tIMP concentration increased proportionally with the concentration of Me-MPR. High Me-tIMP concentration also caused inhibition of PRPP synthesis. Maximal accumulation of PRPP thus occurred at low Me-MPR concentrations. As little as 0.2 microM Me-MPR resulted already after 2 h in maximal inhibition of formation of adenine and guanine nucleotides, caused by inhibition of purine de novo synthesis by Me-tIMP. Under these circumstances increased intracellular PRPP concentrations could be demonstrated, resulting in increased levels of pyrimidine nucleotides. So, in Molt F4 cells, formation of Me-tIMP from Me-MPR results in cytotoxicity by inhibition of purine de novo synthesis.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7683208     DOI: 10.1016/0925-4439(93)90110-m

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  7 in total

Review 1.  Pharmacogenetics in inflammatory bowel disease.

Authors:  Marie Pierik; Paul Rutgeerts; Robert Vlietinck; Severine Vermeire
Journal:  World J Gastroenterol       Date:  2006-06-21       Impact factor: 5.742

Review 2.  The thiopurines: an update.

Authors:  Sally Coulthard; Linda Hogarth
Journal:  Invest New Drugs       Date:  2005-12       Impact factor: 3.850

3.  Intracellular pharmacodynamic studies of the synergistic combination of 6-mercaptopurine and cytosine arabinoside in human leukemia cell lines.

Authors:  L V Ramilo-Torno; V I Avramis
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

4.  Decrease in S-adenosylmethionine synthesis by 6-mercaptopurine and methylmercaptopurine ribonucleoside in Molt F4 human malignant lymphoblasts.

Authors:  E H Stet; R A De Abreu; J P Bökkerink; H J Blom; L H Lambooy; T M Vogels-Mentink; A C de Graaf-Hess; B van Raay-Selten; F J Trijbels
Journal:  Biochem J       Date:  1994-11-15       Impact factor: 3.857

5.  A single point mutation leading to loss of catalytic activity in human thiopurine S-methyltransferase.

Authors:  E Y Krynetski; J D Schuetz; A J Galpin; C H Pui; M V Relling; W E Evans
Journal:  Proc Natl Acad Sci U S A       Date:  1995-02-14       Impact factor: 11.205

6.  Enhancing the Antiviral Potency of Nucleobases for Potential Broad-Spectrum Antiviral Therapies.

Authors:  Ruben Soto-Acosta; Tiffany C Edwards; Christine D Dreis; Venkatramana D Krishna; Maxim C-J Cheeran; Li Qiu; Jiashu Xie; Laurent F Bonnac; Robert J Geraghty
Journal:  Viruses       Date:  2021-12-14       Impact factor: 5.048

7.  Analytical and Sample Preparation Protocol for Therapeutic Drug Monitoring of 12 Thiopurine Metabolites Related to Clinical Treatment of Inflammatory Bowel Disease.

Authors:  Daniel Pecher; Svetlana Dokupilová; Zuzana Zelinková; Maikel Peppelenbosch; Jana Lučeničová; Veronika Mikušová; Peter Mikuš
Journal:  Molecules       Date:  2018-07-17       Impact factor: 4.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.